PortfoliosLab logoPortfoliosLab logo
MRVL vs. ZVRA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MRVL vs. ZVRA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Marvell Technology, Inc. (MRVL) and Zevra Therapeutics Inc. (ZVRA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MRVL achieves a 177.90% return, which is significantly higher than ZVRA's 49.00% return. Over the past 10 years, MRVL has outperformed ZVRA with an annualized return of 38.11%, while ZVRA has yielded a comparatively lower -14.94% annualized return.


MRVL

1D
-3.04%
1M
-15.97%
6M
183.57%
YTD
177.90%
1Y
225.01%
3Y*
56.45%
5Y*
33.34%
10Y*
38.11%

ZVRA

1D
-4.23%
1M
2.93%
6M
57.24%
YTD
49.00%
1Y
6.54%
3Y*
40.34%
5Y*
0.06%
10Y*
-14.94%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MRVL vs. ZVRA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MRVL
Marvell Technology, Inc.
177.90%-22.82%83.79%63.68%-57.48%84.62%80.25%65.74%-23.62%56.89%
ZVRA
Zevra Therapeutics Inc.
49.00%7.43%27.33%42.70%-47.30%-22.23%84.70%-78.71%-56.05%37.29%

Correlation

The correlation between MRVL and ZVRA is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.19

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Apr 16, 2015

0.20

The correlation between MRVL and ZVRA shifts across timeframes, from 0.17 (1 year) to 0.27 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

MRVL:

$206.29B

ZVRA:

$789.19M

EPS

MRVL:

$2.90

ZVRA:

$2.15

PE Ratio

MRVL:

81.42

ZVRA:

6.21

PS Ratio

MRVL:

23.60

ZVRA:

6.31

PB Ratio

MRVL:

11.56

ZVRA:

3.91

Total Revenue (TTM)

MRVL:

$8.72B

ZVRA:

$122.29M

Gross Profit (TTM)

MRVL:

$4.41B

ZVRA:

$104.94M

EBITDA (TTM)

MRVL:

$4.27B

ZVRA:

$149.15M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MRVL vs. ZVRA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRVL
MRVL Risk / Return Rank: 9595
Overall Rank
MRVL Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
MRVL Sortino Ratio Rank: 9393
Sortino Ratio Rank
MRVL Omega Ratio Rank: 9393
Omega Ratio Rank
MRVL Calmar Ratio Rank: 9898
Calmar Ratio Rank
MRVL Martin Ratio Rank: 9696
Martin Ratio Rank

ZVRA
ZVRA Risk / Return Rank: 5252
Overall Rank
ZVRA Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
ZVRA Sortino Ratio Rank: 5252
Sortino Ratio Rank
ZVRA Omega Ratio Rank: 5252
Omega Ratio Rank
ZVRA Calmar Ratio Rank: 5353
Calmar Ratio Rank
ZVRA Martin Ratio Rank: 5151
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRVL vs. ZVRA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Marvell Technology, Inc. (MRVL) and Zevra Therapeutics Inc. (ZVRA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MRVLZVRADifference
Sharpe ratioReturn per unit of total volatility

+2.82

Sortino ratioReturn per unit of downside risk

+2.50

Omega ratioGain probability vs. loss probability

1.44

1.09

+0.35

Calmar ratioReturn relative to maximum drawdown

8.26

0.26

+8.01

Martin ratioReturn relative to average drawdown

18.47

0.45

+18.02

MRVL vs. ZVRA - Sharpe Ratio Comparison

The current MRVL Sharpe Ratio is 3.00, which is higher than the ZVRA Sharpe Ratio of 0.18. The chart below compares the historical Sharpe Ratios of MRVL and ZVRA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MRVL vs. ZVRA - Drawdown Comparison

The maximum MRVL drawdown since its inception was -91.60%, smaller than the maximum ZVRA drawdown of -99.27%. Use the drawdown chart below to compare losses from any high point for MRVL and ZVRA.


Loading charts...

Drawdown Indicators


MRVLZVRADifference

Max Drawdown

Largest peak-to-trough decline

-91.60%

-99.27%

+7.67%

Max Drawdown (1Y)

Largest decline over 1 year

-27.09%

-43.47%

+16.38%

Max Drawdown (3Y)

Largest decline over 3 years

-60.79%

-43.47%

-17.32%

Max Drawdown (5Y)

Largest decline over 5 years

-61.88%

-66.94%

+5.06%

Max Drawdown (10Y)

Largest decline over 10 years

-61.88%

-97.85%

+35.97%

Current Drawdown

Current decline from peak

-25.46%

-96.47%

+71.01%

Average Drawdown

Average peak-to-trough decline

-46.65%

-86.47%

+39.82%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.10%

24.89%

-12.79%

Volatility

MRVL vs. ZVRA - Volatility Comparison

Marvell Technology, Inc. (MRVL) has a higher volatility of 30.44% compared to Zevra Therapeutics Inc. (ZVRA) at 12.44%. This indicates that MRVL's price experiences larger fluctuations and is considered to be riskier than ZVRA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MRVLZVRADifference

Volatility (1M)

Calculated over the trailing 1-month period

30.44%

12.44%

+18.00%

Volatility (6M)

Calculated over the trailing 6-month period

60.87%

40.65%

+20.22%

Volatility (1Y)

Calculated over the trailing 1-year period

74.57%

61.17%

+13.40%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

62.94%

60.33%

+2.61%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

52.52%

80.82%

-28.30%

Dividends

MRVL vs. ZVRA - Dividend Comparison

MRVL's dividend yield for the trailing twelve months is around 0.13%, while ZVRA has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
MRVL
Marvell Technology, Inc.
0.10%0.28%0.22%0.40%0.65%0.21%0.50%0.90%1.48%1.12%1.73%2.72%
ZVRA
Zevra Therapeutics Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

MRVL vs. ZVRA - Financials Comparison

This section allows you to compare key financial metrics between Marvell Technology, Inc. and Zevra Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B20222023202420252026
2.42B
36.22M
(MRVL) Total Revenue
(ZVRA) Total Revenue
Values in USD except per share items

Frequently Asked Questions


MRVL and ZVRA have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

MRVL has higher volatility (30.44%) compared to ZVRA (12.44%). In terms of maximum drawdown, MRVL dropped -91.60% vs ZVRA's -99.27%.

MRVL currently has the higher Sharpe Ratio (3.00 vs 0.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MRVL and ZVRA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer